SY-2101 in APL | --- | --- | --- | --- | |-----------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------|-------| | | | | | | Tamibarotene is a | selective and potent RARa agonist1 | Competitive differentiation of tamibarotene | | | | with tamibarotene | Biologically targeted1 | ✓ | | | | Oral | ✓ | | | | High complete response rates5,6 | ✓ | | of patients with HR-MDS are p ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Karen Hunady - Director, Investor Relations and Corporate Communications Nancy Simonian - President, CEO & Director David Roth - Chief Medical Officer Jason Haas - CFO Conference Call Participants Philip Nadeau - TD Cowen Edward Tenthoff - Piper Sandler & Co. Jason Butler - JMP Securities Mark Breidenbach - Oppenheimer Operator Good morning, and welcome to Syros Pharmaceuticals' First Quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-3772460 (State or Other Jurisdiction of Incorporation or Organ ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Karen Hunady - Director-Investor Relations & Corporate Communications Nancy Simonian - Chief Executive Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen and Company Mark Breidenbach - Oppenheimer Jason Butler - JMP Securities Operator Good morning, and welcome to Syros Pharmaceuticals Fourth Quarter and Full ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-3772460 (State or other jurisdic ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Karen Hunady - Director-Corporate Communications & Investor Relations Nancy Simonian - President & Chief Executive Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Philip Nadeau - Cowen Operator Good day, and welcome to the Q3 2022 Syros Pharmaceuticals, Inc. Earnings Conference Call. At this t ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Courtney Solberg - Manager of Corporate Communications & Investor Relations Nancy Simonian - Chief Executive Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Phil Nadeau - Cowen & Company Jason Butler - JMP Securities Mark Breidenbach - Oppenheimer Operator Good morning, and welcome to Syros Pharmaceuticals Second Quarter 2022 F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-3772460 (State or Other Jurisdiction of Incorporation or Organi ...

An Expression Makes a World of Difference June 2022 Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, research and clinical development plans, collaborations, future operations, future financial position, future revenues ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications and IR Nancy Simonian - CEO Jason Haas - CFO David Roth - Chief Medical Officer Kristin Stephens - Chief Development Office Eric Olson - Chief Scientific Officer Conley Chee - Chief Commercial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Eva Previtera - Cowen Jason Butler - JMP Securities Mark Breidenbach - Oppenheim ...